These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 9337346)

  • 21. [Detection of PSA mRNA from the peripheral blood and pelvic lymph nodes in patients with prostatic cancer by means of reverse transcription-polymerase chain reaction (RT-PCR)].
    Mao H; Hoshi S; Takahashi T; Kaneda T; Wang J; Suzuki K; Orikasa S
    Nihon Hinyokika Gakkai Zasshi; 1998 Jun; 89(6):596-603. PubMed ID: 9666686
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular staging of prostate cancer. II. A comparison of the application of an enhanced reverse transcriptase polymerase chain reaction assay for prostate specific antigen versus prostate specific membrane antigen.
    Cama C; Olsson CA; Raffo AJ; Perlman H; Buttyan R; O'Toole K; McMahon D; Benson MC; Katz AE
    J Urol; 1995 May; 153(5):1373-8. PubMed ID: 7536252
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Incidence of positive pelvic lymph nodes in patients with prostate cancer, a prostate-specific antigen (PSA) level of < or =10 ng/mL and biopsy Gleason score of < or =6, and their influence on PSA progression-free survival after radical prostatectomy.
    Weckermann D; Goppelt M; Dorn R; Wawroschek F; Harzmann R
    BJU Int; 2006 Jun; 97(6):1173-8. PubMed ID: 16686707
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Molecular staging of prostatic cancer with RT-PCR assay for prostate-specific antigen in peripheral blood and lymph nodes. 5 year follow-up.
    Martínez-Piñeiro L; Martínez-Gomariz M; Rios E; Picazo ML; Arriaga HR; Perona R
    Arch Esp Urol; 2007 Dec; 60(10):1.228-1.236. PubMed ID: 18273986
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.
    Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A
    Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Repetitive and site-specific molecular staging of prostate cancer using nested reverse transcriptase polymerase chain reaction for prostate specific antigen and prostate specific membrane antigen.
    Koutsilieris M; Lembessis P; Luu-The V; Sourla A
    Clin Exp Metastasis; 1999; 17(10):823-30. PubMed ID: 11089880
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combined application of RT-PCR and immunohistochemistry on paraffin embedded sentinel lymph nodes of prostate cancer patients.
    Haas CJ; Wagner T; Wawroschek F; Arnholdt H
    Pathol Res Pract; 2005; 200(11-12):763-70. PubMed ID: 15792118
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Detection of micrometastatic prostate cancer cells in lymph nodes by reverse transcriptase-polymerase chain reaction.
    Deguchi T; Doi T; Ehara H; Ito S; Takahashi Y; Nishino Y; Fujihiro S; Kawamura T; Komeda H; Horie M
    Cancer Res; 1993 Nov; 53(22):5350-4. PubMed ID: 7693338
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molecular and immunohistochemical staging of men with seminal vesicle invasion and negative pelvic lymph nodes at radical prostatectomy.
    Potter SR; Mangold LA; Shue MJ; Taylor DC; Lecksell KL; Epstein JI; Walsh PC; Partin AW
    Cancer; 2000 Dec; 89(12):2577-86. PubMed ID: 11135219
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Value of prostate-specific antigen measurements in predicting lymph node involvement in prostatic cancer.
    Arai Y; Yoshiki T; Yamabe H; Yoshida O
    Urol Int; 1990; 45(6):356-60. PubMed ID: 1705062
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Detection of extraprostatic prostate cells utilizing reverse transcription-polymerase chain reaction.
    Su SL; Boynton AL; Holmes EH; Elgamal AA; Murphy GP
    Semin Surg Oncol; 2000; 18(1):17-28. PubMed ID: 10617893
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Predicting the risk of lymph node involvement using the pre-treatment prostate specific antigen and Gleason score in men with clinically localized prostate cancer.
    Roach M; Marquez C; Yuo HS; Narayan P; Coleman L; Nseyo UO; Navvab Z; Carroll PR
    Int J Radiat Oncol Biol Phys; 1994 Jan; 28(1):33-7. PubMed ID: 7505775
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Seminal vesicle biopsy and laparoscopic pelvic lymph node dissection: implications for patient selection in the radiotherapeutic management of prostate cancer.
    Stock RG; Stone NN; Ianuzzi C; Unger P
    Int J Radiat Oncol Biol Phys; 1995 Nov; 33(4):815-21. PubMed ID: 7591888
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Perineural invasion and seminal vesicle involvement predict pelvic lymph node metastasis in men with localized carcinoma of the prostate.
    Stone NN; Stock RG; Parikh D; Yeghiayan P; Unger P
    J Urol; 1998 Nov; 160(5):1722-6. PubMed ID: 9783940
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reverse transcriptase polymerase chain reaction for prostate specific antigen in the management of prostate cancer.
    Gomella LG; Raj GV; Moreno JG
    J Urol; 1997 Aug; 158(2):326-37. PubMed ID: 9224297
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation and comparison of two new prostate carcinoma markers. Free-prostate specific antigen and prostate specific membrane antigen.
    Murphy GP; Barren RJ; Erickson SJ; Bowes VA; Wolfert RL; Bartsch G; Klocker H; Pointner J; Reissigl A; McLeod DG; Douglas T; Morgan T; Kenny GM; Ragde H; Boynton AL; Holmes EH
    Cancer; 1996 Aug; 78(4):809-18. PubMed ID: 8756376
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Implications of prostate micrometastases in pelvic lymph nodes: an archival tissue study.
    Edelstein RA; Zietman AL; de las Morenas A; Krane RJ; Babayan RK; Dallow KC; Traish A; Moreland RB
    Urology; 1996 Mar; 47(3):370-5. PubMed ID: 8633404
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of clinical staging algorithms and 111indium-capromab pendetide immunoscintigraphy in the prediction of lymph node involvement in high risk prostate carcinoma patients.
    Polascik TJ; Manyak MJ; Haseman MK; Gurganus RT; Rogers B; Maguire RT; Partin AW
    Cancer; 1999 Apr; 85(7):1586-92. PubMed ID: 10193950
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Detecting metastatic pelvic lymph nodes by 18F-2-deoxyglucose positron emission tomography in patients with prostate-specific antigen relapse after treatment for localized prostate cancer.
    Chang CH; Wu HC; Tsai JJ; Shen YY; Changlai SP; Kao A
    Urol Int; 2003; 70(4):311-5. PubMed ID: 12740497
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of immunohistochemistry with reverse transcription-PCR for the detection of micrometastatic prostate cancer in lymph nodes.
    Shariat SF; Roudier MP; Wilcox GE; Kattan MW; Scardino PT; Vessella RL; Erdamar S; Nguyen C; Wheeler TM; Slawin KM
    Cancer Res; 2003 Aug; 63(15):4662-70. PubMed ID: 12907647
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.